Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maximizing discovery efficiency with a computationally driven fragment approach.

William R Moore1

  • 1Locus Pharmaceuticals Inc, 4 Valley Square, 512 Township Line Road, Blue Bell, PA 19422, USA. wmoore@locuspharma.com

Current Opinion in Drug Discovery & Development
|May 17, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment.

Clinical genitourinary cancer·2020
Same author

Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.

The Journal of clinical investigation·2017
Same author

Design and optimization of highly-selective fungal CYP51 inhibitors.

Bioorganic & medicinal chemistry letters·2014
Same author

Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.

Bioorganic & medicinal chemistry letters·2014
Same author

Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent.

Journal of medicinal chemistry·2010
Same author

Early prosthetic complications after unipolar hemiarthroplasty.

ANZ journal of surgery·2006
Same journal

Microreactors for continuous processing – How close to commercial utility?

Current opinion in drug discovery & development·2010
Same journal

Synthesis of polyketide natural products and analogs as promising anticancer agents.

Current opinion in drug discovery & development·2010
Same journal

Enantioselective synthesis of substituted oxindoles and spirooxindoles with applications in drug discovery.

Current opinion in drug discovery & development·2010
Same journal

Eliminating pharmaceutical impurities: Recent advances in detection techniques.

Current opinion in drug discovery & development·2010
Same journal

Stereoselective heterocycle synthesis through oxidative carbon-hydrogen bond activation.

Current opinion in drug discovery & development·2010
Same journal

Catalysis in aqueous media for the synthesis of drug-like molecules.

Current opinion in drug discovery & development·2010
See all related articles

Locus Pharmaceuticals developed a fragment-driven, computational approach for efficient small-molecule drug discovery. This method rapidly identifies potent drug candidates, improving cost-effectiveness and speed in pharmaceutical research.

Area of Science:

  • Drug discovery and development
  • Computational chemistry
  • Medicinal chemistry

Background:

  • The pharmaceutical industry seeks efficient computational methods for novel drug candidate design.
  • Current drug discovery processes can be time-consuming and expensive.
  • A need exists for technology that rapidly provides potent molecules for prioritization.

Purpose of the Study:

  • To describe the progress of Locus Pharmaceuticals' fragment-driven, computationally directed approach to small-molecule discovery.
  • To demonstrate the efficiency and cost-effectiveness of this novel drug design strategy.

Main Methods:

  • Utilizing a fragment-driven methodology.
  • Employing a computationally directed strategy for small-molecule discovery.

Related Experiment Videos

  • Prioritizing synthesized molecules based on patentability, protein-ligand interactions, synthetic ease, selectivity, and pharmacology.

    • Main Results:

    • Successful application of the fragment-driven, computational approach.
    • Demonstrated efficiency in identifying lead compounds.
    • Realized cost-effectiveness in drug discovery programs.

    Conclusions:

    • The fragment-driven, computationally directed approach significantly enhances drug discovery efficiency.
    • This method provides a cost-effective means to identify and prioritize potent small-molecule drug candidates.
    • Locus Pharmaceuticals' strategy represents a significant advancement in computational drug design.